|Articles|January 15, 2003

BioPharm International-01-01-2003
Volume 16
Issue 1

Virus Inactivation in the 1990s and into the 21st Century: Part 4, Culture Media, Biotechnology Products, and Vaccines

by Gail Sofer, BioReliance With West Nile virus in the news, viral inactivation is under public scrutiny. Yet, the culture media, the therapeutic product, and the potential viral contaminants can all affect the inactivation method chosen during production. Viral inactivation techniques ? those tried or used in manufacturing or in final biopharmaceuticals, vaccines, and media products ? have been gathered from recent scientific literature and organized in this article series as an addition to your process development toolbox.

To view a PDF of this article from the BioPharm International archives, click this link

Articles in this issue

almost 24 years ago

Article

Biotech World: Canada's Supreme Court says "No" to Harvard Mouse

almost 24 years ago

Article

Rethinking the Economics of Chromatography: New Technologies and Hidden Costs

almost 24 years ago

Article

Outsourcing Outlook: Using Virtual Private Networks to Gain Competitive Advantage

almost 24 years ago

Article

Inside Washington: Coverage and Consolidation ? Key Issues for Biotech Companies

almost 24 years ago

Article

Employing Near-Infrared Spectroscopic Methods of Analysis for Fermentation Monitoring and Control: Part 2, Implementation Strategies

almost 24 years ago

Article

Guest Editorial: At the Governance Crossroad

almost 24 years ago

Article

Reducing Costs by Facility Design

almost 24 years ago

Article

Guidelines for Optimization and Scale-Up in Preparative Chromatography

almost 24 years ago

Article

Analytical Advances: Funneling a Flood Tide of Data ? New Software Accelerates Bioinformatic Analyses

almost 24 years ago

Article

Survival Strategies: Board Compensation Changing with the Times

Stay at the forefront of biopharmaceutical innovation. Subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Related to this article

October 22nd, 2026

Turn Supply Chain Data Into Decisions Before Shortages Reach Patients, Says RELEX’s Rohit Tripathi

Rohit Tripathi, vice president of industry strategy, consumer packaged goods, and manufacturing at RELEX Solutions, explains where cold-chain planning still breaks down and why biopharma supply chain leaders should use AI to act on data sooner, with humans making the final call.

October 22nd, 2026

The BioPharm Brief: Kidney Approval, Retinal Cell Therapy, and a Breast Cancer Trial Shift

The FDA grants accelerated approval to Ultomiris for IgA nephropathy, Alcon acquires Neurotech and its MacTel cell therapy for $550 million, and BioNTech and Bristol Myers Squibb add Trodelvy to a phase 3 trial in triple-negative breast cancer.

Technologist in white protective uniform controlling industrial process using tablet computer. | Image credit: © littlewolf1989 - © littlewolf1989 - stock.adobe.com

October 22nd, 2026

Zylidac Bio to Scale Prolific's Optogenetic Cell Line Platform to GMP

Zylidac will test whether optogenetic cell lines that hit 21 g/L in small-scale CHO runs can deliver higher-yield complex biologics at GMP scale.

Structure of human eye. In side view. | Image credit: © svetazi - © svetazi - stock.adobe.com

October 22nd, 2026

Alcon Pays $550 Million for Neurotech and Its MacTel Cell Therapy

Revakinagene taroretcel (Encelto), the only FDA-approved MacTel therapy, slowed photoreceptor loss by up to 54.8% vs sham in phase 3 trials.

3D cross-section illustration of breast tissue showing pink lobes, milk ducts converging toward the nipple, and a dark red clustered mass representing a tumor. | Image Credit: © Design cells - stock.adobe.com

October 22nd, 2026

BioNTech, BMS to Pair Pumitamig With Trodelvy in Phase 3 First-Line TNBC Trial

BioNTech and Bristol Myers Squibb will replace chemotherapy with Gilead’s TROP2-directed ADC sacituzumab govitecan in the Phase 3 ROSETTA Breast-01 trial of PD-L1×VEGF-A bispecific pumitamig in PD-L1-low or -negative TNBC.

A clinician in a white coat with a stethoscope points a pen at an anatomical model showing the kidneys, renal blood vessels, aorta, vena cava, and ureters. | Image Credit: © Yanisa - stock.adobe.com

October 22nd, 2026

FDA Grants Accelerated Approval to Ultomiris as First C5 Inhibitor for IgA Nephropathy

Alexion’s ravulizumab won accelerated approval to reduce proteinuria in adults with IgA nephropathy after the Phase 3 I CAN trial showed a 43.4% placebo-adjusted reduction at Week 34.

October 21st, 2026

The BioPharm Brief: Insulin Supply Security, a Bispecific Head-to-Head, and Long-Acting HIV Antibodies

Sanofi breaks ground on an EU-backed insulin API plant in Frankfurt, Summit and ECOG-ACRIN launch a phase 2/3 trial of ivonescimab in first-line biliary tract cancer, and TaiMed’s anti-CD4 antibody TMB-365 lowers HIV viral load in phase 1.

October 21st, 2026

Reshoring Should Be Judged by Risk Removed, Not Factories Moved, Says RELEX’s Rohit Tripathi

Rohit Tripathi, vice president of industry strategy, consumer packaged goods, and manufacturing at RELEX Solutions, explains what is driving biopharma reshoring, how USMCA uncertainty complicates sourcing for biologics, and where cold-chain visibility still breaks down.

Virus Inactivation in the 1990s and into the 21st Century: Part 4, Culture Media, Biotechnology Products, and Vaccines

Articles in this issue

Related to this article

Trending on BioPharm International

Sanofi Begins Construction of EU-Backed Insulin Plant in Frankfurt

Zylidac Bio to Scale Prolific's Optogenetic Cell Line Platform to GMP

TaiMed’s Anti-CD4 Antibody TMB-365 Reduces HIV Viral Load in Phase 1, Supporting Long-Acting Combination Regimens

Akeso's Ivonescimab Enters Phase 2/3 Biliary Tract Cancer Trial in US

Nano24's Inhaled EXO-CD24 Cuts ARDS Mortality in Phase 2b Trial